<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03483753</url>
  </required_header>
  <id_info>
    <org_study_id>62586316.6.0000.0065</org_study_id>
    <nct_id>NCT03483753</nct_id>
  </id_info>
  <brief_title>Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery</brief_title>
  <acronym>VANCSIII</acronym>
  <official_title>Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery: a Randomized and Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to evaluate the effect of vasopressin compared to
      norepinephrine on the clinical complications of patients with vasospastic shock after
      noncardiac surgeries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Systemic Inflammatory Response Syndrome (SIRS) is a common complication after non-cardiac
      surgery, impacting negatively on patient outcome and with high incidence rates. Vasoplegic
      syndrome is the most serious complication of SIRS and can happen after any type of surgery.
      The etiology of the vasoplegic syndrome has not yet been fully elucidated, but is known to
      occur more frequently in patients at high surgical risk, submitted to major surgeries, or in
      the presence of perioperative complications and patients with comorbidities. In this
      circumstance, the depletion of vasopressin stocks is described, which may contribute to the
      refractoriness of the shock and the lack of response to the catecholaminergic drugs. The
      standard treatment of perioperative vasoplegia has been adequate volume replacement and
      administration of vasopressors, with norepinephrine being the most commonly used. However, it
      is known that norepinephrine may have deleterious effects on the body and in 20% of patients
      with vasospastic shock it is ineffective. Previous studies have suggested benefits of adding
      vasopressin in refractory situations, especially in septic shock. Recently the VANCS study
      (Vasopressin or norepinephrine in the vasopregic shock after cardiac surgery: double-blind,
      controlled and randomized study) demonstrated superiority of vasopressin in the reversion of
      vasoplegic shock after cardiac surgery, as well as a lower incidence of renal insufficiency,
      atrial fibrillation and shorter hospitalization time. (Anesthesiology. 2017
      Jan;126(1):85-93.)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence between groups of a composite outcome of all-cause mortality, cardiovascular and renal complications after high-risk non-cardiac surgeries</measure>
    <time_frame>30 days</time_frame>
    <description>Cardiovascular complications include: stroke, acute myocardial infarction, cardiogenic shock, nonfatal myocardial injury, and ventricular or supraventricular arrhythmias.
Renal complications: Acute renal failure with AKIN stage 1 or higher or renal support therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>mortality rate of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute myocardial infarction</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>to compare between groups the incidence of acute myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiogenic shock</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>to compare between groups the incidence of cardiogenic shock</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular and / or supraventricular arrhythmia</measure>
    <time_frame>30 days</time_frame>
    <description>to compare between groups the incidence of Ventricular and / or supraventricular arrhythmia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute respiratory distress syndrome (ARDS)</measure>
    <time_frame>30 days</time_frame>
    <description>to compare between groups the incidence of Acute respiratory distress syndrome (ARDS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke and transient ischemic attack</measure>
    <time_frame>30 days</time_frame>
    <description>to compare between groups the incidence of Stroke and transient ischemic attack</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delirium</measure>
    <time_frame>30 days</time_frame>
    <description>to compare between groups the incidence of Delirium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute renal failure (AKIN 1 or more)</measure>
    <time_frame>30 days</time_frame>
    <description>to compare between groups the incidence of Acute renal failure (AKIN 1 or more)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of time in the Intensive Care Unit (ICU) and hospital</measure>
    <time_frame>30 days</time_frame>
    <description>Length of time in the Intensive Care Unit (ICU) and hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of mechanical ventilation</measure>
    <time_frame>30 days</time_frame>
    <description>Length of mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Septic shock</measure>
    <time_frame>30 days</time_frame>
    <description>to compare between groups the incidence of septic shock</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital and ICU readmission rate</measure>
    <time_frame>30 days</time_frame>
    <description>hospital and ICU readmission rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation</measure>
    <time_frame>30 days</time_frame>
    <description>number of patients who required reoperation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>to compare the incidence of severe adverse outcomes defined as mesenteric ischemia, digital ischemia, hyponatremia (Na&lt;130mEq/L), myocardial infarction or stroke</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">338</enrollment>
  <condition>Circulatory Shock</condition>
  <condition>Non-cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Vasopressin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinded vasopressin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norepinephrine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blinded norepinephrine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressin</intervention_name>
    <description>Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure &lt;65 mmHg after fluid replacement.
Continuous infusion of the drug at doses ranging from 0.01 U / min to 0.06 U / min</description>
    <arm_group_label>Vasopressin group</arm_group_label>
    <other_name>Blinded Vasopressin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure &lt;65 mmHg after fluid replacement. Continuous infusion of the drug at doses ranging from 0.1 mcg / kg / min to 1.0 mcg / kg / min.</description>
    <arm_group_label>Norepinephrine group</arm_group_label>
    <other_name>Blinded Norepinephrine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than 18 years;

          -  Patients undergoing high-risk non-cardiac surgery;

          -  vasopressor need within 24 hours after surgery, defined as mean arterial pressure
             (MAP) &lt;65 mmHg after volume resuscitation with at least 1 liter of crystalloid
             solution (Ringer's lactate) and maintaining a cardiac index&gt; 2.2 ml / min / m²;

          -  Signature of the informed consent form.

        Exclusion Criteria:

          -  Allergy to vasoactive drugs;

          -  Previous use of vasopressor;

          -  Gestation;

          -  Presence of Raynaud's phenomenon, altered Allen's test, systemic sclerosis or
             vasospastic diathesis;

          -  Severe hyponatremia (Na &lt;130 mEq / L);

          -  Acute mesenteric ischemia;

          -  Acute coronary syndrome;

          -  Participation in another study;

          -  Refusal to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliano P Almeida, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tais F Szeles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tais F Szeles, MD</last_name>
    <phone>+5519992859415</phone>
    <email>taisfelix@usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ludhmila A Hajjar, MD, PhD</last_name>
    <phone>+55993194401</phone>
    <email>ludhmila@terra.com.br</email>
  </overall_contact_backup>
  <reference>
    <citation>Levin MA, Lin HM, Castillo JG, Adams DH, Reich DL, Fischer GW. Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome. Circulation. 2009 Oct 27;120(17):1664-71. doi: 10.1161/CIRCULATIONAHA.108.814533. Epub 2009 Oct 12.</citation>
    <PMID>19822810</PMID>
  </reference>
  <reference>
    <citation>Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001 Aug 23;345(8):588-95. Review.</citation>
    <PMID>11529214</PMID>
  </reference>
  <reference>
    <citation>Gkisioti S, Mentzelopoulos SD. Vasogenic shock physiology. Open Access Emerg Med. 2011 Jan 6;3:1-6. doi: 10.2147/OAEM.S10388. eCollection 2011. Review.</citation>
    <PMID>27147845</PMID>
  </reference>
  <reference>
    <citation>Teboul JL, Monnet X. Detecting volume responsiveness and unresponsiveness in intensive care unit patients: two different problems, only one solution. Crit Care. 2009;13(4):175. doi: 10.1186/cc7979. Epub 2009 Aug 10.</citation>
    <PMID>19678915</PMID>
  </reference>
  <reference>
    <citation>Brown SM, Lanspa MJ, Jones JP, Kuttler KG, Li Y, Carlson R, Miller RR 3rd, Hirshberg EL, Grissom CK, Morris AH. Survival after shock requiring high-dose vasopressor therapy. Chest. 2013 Mar;143(3):664-671. doi: 10.1378/chest.12-1106.</citation>
    <PMID>22911566</PMID>
  </reference>
  <reference>
    <citation>Morales D, Madigan J, Cullinane S, Chen J, Heath M, Oz M, Oliver JA, Landry DW. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation. 1999 Jul 20;100(3):226-9.</citation>
    <PMID>10411844</PMID>
  </reference>
  <reference>
    <citation>Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D; VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008 Feb 28;358(9):877-87. doi: 10.1056/NEJMoa067373.</citation>
    <PMID>18305265</PMID>
  </reference>
  <reference>
    <citation>Russell JA. Vasopressin, Norepinephrine, and Vasodilatory Shock after Cardiac Surgery: Another &quot;VASST&quot; Difference? Anesthesiology. 2017 Jan;126(1):9-11.</citation>
    <PMID>27841820</PMID>
  </reference>
  <results_reference>
    <citation>Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, Rhodes A, Landoni G, Osawa EA, Melo RR, Sundin MR, Grande SM, Gaiotto FA, Pomerantzeff PM, Dallan LO, Franco RA, Nakamura RE, Lisboa LA, de Almeida JP, Gerent AM, Souza DH, Gaiane MA, Fukushima JT, Park CL, Zambolim C, Rocha Ferreira GS, Strabelli TM, Fernandes FL, Camara L, Zeferino S, Santos VG, Piccioni MA, Jatene FB, Costa Auler JO Jr, Filho RK. Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery: The VANCS Randomized Controlled Trial. Anesthesiology. 2017 Jan;126(1):85-93.</citation>
    <PMID>27841822</PMID>
  </results_reference>
  <results_reference>
    <citation>Takenaka K, Ogawa E, Wada H, Hirata T. Systemic inflammatory response syndrome and surgical stress in thoracic surgery. J Crit Care. 2006 Mar;21(1):48-53; discussion 53-5.</citation>
    <PMID>16616623</PMID>
  </results_reference>
  <results_reference>
    <citation>Haga Y, Beppu T, Doi K, Nozawa F, Mugita N, Ikei S, Ogawa M. Systemic inflammatory response syndrome and organ dysfunction following gastrointestinal surgery. Crit Care Med. 1997 Dec;25(12):1994-2000.</citation>
    <PMID>9403749</PMID>
  </results_reference>
  <results_reference>
    <citation>Dubin A, Pozo MO, Casabella CA, Pálizas F Jr, Murias G, Moseinco MC, Kanoore Edul VS, Pálizas F, Estenssoro E, Ince C. Increasing arterial blood pressure with norepinephrine does not improve microcirculatory blood flow: a prospective study. Crit Care. 2009;13(3):R92. doi: 10.1186/cc7922. Epub 2009 Jun 17.</citation>
    <PMID>19534818</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2018</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Tais Felix Szeles</investigator_full_name>
    <investigator_title>PhD student</investigator_title>
  </responsible_party>
  <keyword>Vasopressin</keyword>
  <keyword>Norepinephrine</keyword>
  <keyword>Post-operative</keyword>
  <keyword>Critical Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

